Clinical Trial Update: Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial [Phase 2]

View source ↗

Summary

A Phase 2 randomized neoadjuvant trial of adebrelimab for resectable small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Adebrelimab (adebrelimab)

Snippet

Sponsor: Tang-Du Hospital | Conditions: Small Cell Lung Cancer (SCLC) | Phase 2 | Status: RECRUITING